Oncology Reimbursement Report 2011-2012

Insurance spending on specialty products is exploding – and oncologics are one of the key drivers. More than ever, payers are looking for ways to bend the cost curve. Increasingly they’re targeting specific drugs for special treatment. And for the first time, they’re preparing strategies to respond to drugs still in the pipeline, the candidates on which drug companies are increasingly depending for growth. Oncology Reimbursement Report 2011-2012 provides an in-depth assessment of how U.S. payers are currently responding, and will respond in the future, to cancer therapies in general and to specific marketed and pipeline products. Exploiting its proprietary network of managed care medical and pharmacy directors, Oncology Reimbursement Report 2011-2012 provides a comprehensive survey of 55 health plans, covering more than 150 million lives in Commercial, Medicare and Medicaid segments.